Cytek Biosciences Acquires Flow Cytometry Business from DiaSorin
Cytek Biosciences has signed an agreement with DiaSorin subsidiary Luminex to acquire substantially all of its assets related to the Flow Cytometry and Imaging (FCI) business unit. The acquisition will expand Cytek’s global footprint and add two product lines, the Amnis and Guava series of flow cytometers, to its existing portfolio, Cytek said.
Financial details of the transaction were not disclosed.
The sale is expected to close within 30 days, subject to customary closing conditions. The companies dated the announcement of the transaction Feb. 13.
The FCI business unit, acquired by Luminex in October 2018 for $75 million from MilliporeSigma, is based on both conventional flow cytometry and image-based flow cytometry instrumentation. The unit includes dedicated commercial, operations, R&D, and supporting personnel, as well as an existing installed base of more than 7000 instruments.
In November 2021, Cytek acquired the cell analysis business of Tonbo Biosciences, which included a portfolio of life science research reagents related to flow cytometry as well as other methods. The addition came less than a year after Cytek closed its $120 million series D funding round.
/Buyers_Guide/Cytek_Biosciences_Inc/c31692
/Buyers_Guide/Luminex_Corp/c16526